Rapid Micro outlines at least 27 validations in 2026 while targeting positive cash flow by end of 2028 (NASDAQ:RPID)
· seekingalpha.com
Rapid Micro Biosystems (RPID) Q2 2026 earnings call: revenue growth, record consumables, margin ramp, and guidance.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...